izpis_h1_title_alt

Commercially available molecular tests for human papillomaviruses : a global overview
ID Poljak, Mario (Avtor), ID Oštrbenk Valenčak, Anja (Avtor), ID Gimpelj Domjanič, G. (Avtor), ID Xu, Lan (Avtor), ID Arbyn, Marc (Avtor)

.pdfPDF - Predstavitvena datoteka, prenos (901,18 KB)
MD5: 563C56923FAA3F6C750C970B7B8C478E
URLURL - Izvorni URL, za dostop obiščite https://www.sciencedirect.com/science/article/pii/S1198743X20301798 Povezava se odpre v novem oknu

Izvleček
Background: Molecular tests for detection of human papillomaviruses (HPVs) play a crucial role in the prevention of cervical cancer, including recently announced elimination efforts. HPV testing is a recommended approach for cervical cancer screening of women over 30 and for management of those with precancerous cervical lesions. In addition, they are widely used in epidemiological studies, HPV surveillance and vaccination impact monitoring. Objectives: The aim was to provide an updated 2020 inventory of commercial molecular HPV tests available on the market. Sources: Data were retrieved from internal files, and a detailed search using Medline/Pubmed, Web of Science, Scopus, Google Scholar, Google and Bing, without language or period restrictions, was performed in September 2019 and again in January 2020. Content: We identified 254 distinct commercial HPV tests and at least 425 test variants available on the global market in 2020, which represents a 31% and 235% increase in the number of distinct tests and variants, respectively, compared with the previous inventory performed in 2015. Although the proportion of commercially available HPV tests with at least one peer-reviewed publication has increased over the past decade, 60% of the HPV tests on the global market are still without a single peer-reviewed publication. Furthermore, 82% of tests lack any published analytical and/or clinical evaluation, and over 90% are not evaluated in line with consensus requirements that ensure safe use in clinical settings. Implications: Significant challenges and scope for improvement still exist for both the HPV scientific community and the manufacturers of HPV tests. The latter must put more effort into validating their products, in agreement with standardized procedures, including all steps of HPV testing and various clinical specimens. High throughput capacity and point-of-care HPV tests are needed, both with affordable prices.

Jezik:Angleški jezik
Ključne besede:cervical cancer, human papillomaviruses, commercial tests, HPV, screening
Vrsta gradiva:Članek v reviji
Tipologija:1.02 - Pregledni znanstveni članek
Organizacija:MF - Medicinska fakulteta
Status publikacije:Objavljeno
Različica publikacije:Objavljena publikacija
Leto izida:2020
Št. strani:Str. 1144-1150
Številčenje:Vol. 26, iss. 9
PID:20.500.12556/RUL-137785 Povezava se odpre v novem oknu
UDK:618.1
ISSN pri članku:1198-743X
DOI:10.1016/j.cmi.2020.03.033 Povezava se odpre v novem oknu
COBISS.SI-ID:27596547 Povezava se odpre v novem oknu
Datum objave v RUL:30.06.2022
Število ogledov:461
Število prenosov:108
Metapodatki:XML RDF-CHPDL DC-XML DC-RDF
:
Kopiraj citat
Objavi na:Bookmark and Share

Gradivo je del revije

Naslov:Clinical microbiology and infection
Založnik:Elsevier, European Society of Clinical Microbiology and Infectious Diseases
ISSN:1198-743X
COBISS.SI-ID:71154 Povezava se odpre v novem oknu

Licence

Licenca:CC BY-NC-ND 4.0, Creative Commons Priznanje avtorstva-Nekomercialno-Brez predelav 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by-nc-nd/4.0/deed.sl
Opis:Najbolj omejujoča licenca Creative Commons. Uporabniki lahko prenesejo in delijo delo v nekomercialne namene in ga ne smejo uporabiti za nobene druge namene.

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:rak materničnega vratu, človeški papiloma virusi, komercialni testi

Projekti

Financer:EC - European Commission
Program financ.:FP7
Številka projekta:603019
Naslov:Comparing health services interventions for the prevention of HPV-related cancer
Akronim:COHEAHR

Financer:EC - European Commission
Program financ.:H2020
Številka projekta:847845
Naslov:Risk-based screening for cervical cancer
Akronim:RISCC

Financer:ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Številka projekta:P3-0083
Naslov:Odnosi parazitskega obstajanja

Podobna dela

Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:

Nazaj